Efficacy and Safety of Azilsartan Compared to Olmesartan Medoxomil in Chinese Participants With Grade I or II Essential Hypertension

Essential Hypertension Clinical Trial

Official title:

A Phase 3, Double-Blind, Randomized, Parallel-Group Study to Evaluate the Efficacy and Safety of Azilsartan Compared to Olmesartan Medoxomil in Chinese Participants With Grade I or II Essential Hypertension

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02407210
• Other study ID #: HR-AQST-2014
• Status: Recruiting
• Phase: Phase 3
• First received: March 30, 2015
• Last updated: March 30, 2015
• Start date: January 2015

Study information

• Verified date: January 2015
• Source: Jiangsu HengRui Medicine Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Health authority: China: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

To investigate the efficacy and safety of azilsartan compared to olmesartan medoxomil in patients with grade I or II essential hypertension

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 304
• Est. primary completion date: October 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Both sexes. eighteen years or older and no more than 70 years at the time of informed consent

2. Grade I or II essential hypertension

3. Both sitting systolic and diastolic blood pressures at Week 0 during the run-in period meet the following criteria:

Sitting systolic blood pressure: greater than or equal to 150 mmHg and less than 180 mmHg

Sitting diastolic blood pressure: greater than or equal to 95 mmHg and less than 110 mmHg

4. Able to understand the content of the study and comply with the study and to give informed consent in writing before participating in the study

Exclusion Criteria:

1. Secondary hypertension, grade III hypertension (sitting systolic blood pressure greater than or equal to 180 mmHg or sitting diastolic blood pressure greater than or equal to 110 mmHg), or malignant hypertension,hypertensive emergencies,hypertensive urgencies

2. The following circulatory-related diseases or symptoms:

(1) Cardiac disease: angina pectoris; valvular stenosis; atrial fibrillation; the following diseases requiring medication: congestive heart failure or arrhythmia; (2) Cerebrovascular disorder: cerebral infarction, cerebral hemorrhage (onset within 24 weeks before start of the screening period), transient ischemic attack (onset of an attack within 24 weeks before start of the screening period); (3) Vascular disease: arteriosclerosis obliterans with symptoms of intermittent claudication; (4) Progressive hypertensive retinopathy: hemorrhage, exudation, or papilledema (observed within 24 weeks after start of the screening period)

3. Decrease in sitting diastolic blood pressure by 8 mmHg or more at the end of the run-in period (Week 0) compared to the start of the screening period

4. Day/night reversal, e.g., nightshift worker

5. Unilateral or bilateral renal artery stenosis

6. Clinically apparent hepatic and renal impairment (e.g., with AST and ALT values of 2.5 x upper limit of normal or higher, with serum creatinine value of 1.5 x upper limit of normal or higher during the screening period)

7. Hyperkalemia (with a laboratory value of 5.5 mEq/L or higher during the run-in period)

8. Malignant tumor

9. Compliance with the study drug of less than 80% during the run-in period

10. Poorly-controlled diabetes mellitus (fasting plasma glucose greater than 11mmol/L),and/or complications (kidney disease, peripheral neuropathy) at Screening.

11. History of hypersensitivity or allergy to olmesartan medoxomil tablets and related drugs (ARB, ACE inhibitors, and renin inhibitors)

12. History of drug abuse (defined as illegal drug use) or alcohol dependency within 2 years before start of the screening period

13. Requirement of the excluded treatment

14. Pregnant or lactating women

15. Participation in another clinical trial or post-marketing clinical trial within 30 days before start of the screening period

16. Dangerous machinery operator such as aerial worker,motor vehicle driver

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Essential Hypertension
• Hypertension

Intervention

Drug:
• azilsartan

• Olmesartan medoxomil

Locations

Country	Name	City	State
China	Beijing ANZHEN Hospital	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Jiangsu HengRui Medicine Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Trough sitting diastolic blood pressure (change from end of the run-in period to end of the treatment period)		16 weeks	No
Secondary	Trough sitting systolic blood pressure (change from end of the run-in period to end of the treatment period)		16 weeks	No
Secondary	Trough sitting diastolic and systolic blood pressure (change from end of the run-in period to Week 8 of the treatment period)		8 weeks	No
Secondary	Trough sitting diastolic and systolic blood pressures at each evaluation		2 weeks	No
Secondary	responder rate; rate of patients with normalized blood pressure	Responder is defined as a =20mmHg decrease in sitting trough SBP and a =10mmHg decrease in sitting trough DBP,or a sitting trough SBP of <140mmHg and a sitting trough DBP of <90mmHg;normalized blood pressure is defined as a sitting trough SBP of <140mmHg and a sitting trough DBP of <90mmHg.	8 weeks and 16 weeks	No
Secondary	evaluation by ABPM (1: 24-hour mean change in diastolic and systolic blood pressures, 2: Trough/Peak ratio of diastolic and systolic blood pressures)(change from end of the run-in period to Week 14 of the treatment period)		14 weeks	No